Chimerix’s (CMRX) Neutral Rating Reaffirmed at HC Wainwright

Chimerix (NASDAQ:CMRX)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $8.55 price target on the biopharmaceutical company’s stock, down from their previous price target of $11.00. HC Wainwright’s price objective points to a potential upside of 1.48% from the company’s current price.

Separately, Wedbush reiterated an “outperform” rating and issued a $7.00 target price (up from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

Chimerix Trading Up 69.9 %

CMRX traded up $3.47 during trading on Wednesday, hitting $8.43. 103,968,344 shares of the company traded hands, compared to its average volume of 1,904,366. The company has a market cap of $757.71 million, a PE ratio of -8.96 and a beta of 0.32. The stock’s 50-day simple moving average is $4.04 and its two-hundred day simple moving average is $2.17. Chimerix has a 1 year low of $0.75 and a 1 year high of $8.44.

Insider Buying and Selling at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 20,760 shares of company stock worth $91,175 over the last 90 days. 13.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Chimerix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Stoneridge Investment Partners LLC raised its stake in shares of Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Chimerix in the 4th quarter worth about $2,626,000. Finally, Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.